AstraZeneca is teaming up with Oracle to refine clinical research, in the latest artificial-intelligence partnership in the ...

Oct 21 (Reuters) - AstraZeneca said on Wednesday the US Food and Drug Administration granted accelerated approval for its ...

AstraZeneca said it received U.S. approval for its Ultomiris drug as a treatment for foamy urine in adults with immunoglobulin A nephropathy, a rare condition that can lead to chronic kidney disease.

The accelerated approval makes Ultomiris, or ravulizumab, the first and only C5 complement inhibitor approved for this use. Novartis' Fabhalta, or iptacopan, is also approved for this indication but ...

Jefferies, the investment bank, estimates a 59% probability that AstraZeneca PLC (LSE:AZN, NYSE:AZN)’s zibotentan succeeds in ...

AstraZeneca and Oracle team up on AI, aiming to speed up clinical trials and improve patient care pathways, with the first ...

Pascal Soriot spoke exclusively with CNBC from the site of AstraZeneca's new $1 billion R&D facility in Kendall Square in Cambridge, Massachusetts.

AstraZeneca PLC (NYSE:AZN) is lagging the broader market this year so far, with shares declining by over 8%. The ...

The drugmaker will pay AI therapeutics company Insitro $40 million upfront and up to $1.46 billion subject to meeting targets ...

AstraZeneca agrees a $40m upfront deal with insitro to use AI in drug discovery for MASH and cardiomyopathies. Read more.

Oracle kicked off the year by launching its Oracle Life Sciences AI Data Platform, which it touted as using generative AI, ...

By Patrick Wingrove LONDON, Oct 15 (Reuters) - AstraZeneca has teamed up with artificial intelligence biotech company insitro ...